HOME >> BIOLOGY >> NEWS
'Cookbook recipes' would cure disease with nontoxic DNA delivery systems

CHAMPAIGN, Ill. -- Scientists studying the structure and interaction of negatively charged lipids and DNA molecules have created a "cookbook" for a class of nontoxic DNA delivery systems that will assist doctors and clinicians in the safe and effective delivery of genetic medicine.

As reported in the Aug. 9 issue of the Proceedings of the National Academy of Sciences, researchers have now performed a careful, comprehensive study to see how negatively charged lipids stick to negatively charged DNA and self-organize into structures.

"Many research groups have made concoctions with ingredients in different proportions and then assessed their effectiveness in gene delivery, but this is hard and requires a lot of intuition," said Gerard Wong, a professor of materials science and engineering, physics, and bioengineering at the University of Illinois at Urbana-Champaign, and corresponding author of the paper.

"By understanding some of the physics, we now have recipes for assembling delivery systems with different structures, which can have intrinsically different, controllable DNA delivery efficiencies," Wong said. "We found that the same family of structures are generated for many different ions."

Gene therapy is one of the most promising strategies for developing cures for many hereditary and acquired diseases. Protocols have been approved for treating cancer, cystic fibrosis and neuromuscular disorders, for example, but delivering DNA to the proper location and getting the right amount of DNA expression without killing innocent cells has become the Achilles' heel in DNA delivery.

Positively charged (cationic) synthetic molecules will readily bond to negatively charged DNA molecules and have been used for DNA delivery, but these cationic molecules are often toxic to cells, Wong said. An alternative is to use naturally occurring negatively charged (anionic) lipids that won't harm cells.

"The problem then becomes: 'How do you
'"/>

Contact: James E. Kloeppel, Physical Sciences Editor
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
10-Aug-2005


Page: 1 2

Related biology news :

1. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
2. The bee that would be queen
3. Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?
4. 2-protein team would be lost without each other
5. Healthy coastal wetlands would adapt to rising oceans
6. Is it ethical for scientists to do research abroad that would be forbidden at home?
7. Designer babies - what would you do for a healthy baby?
8. New discovery: If it werent for this enzyme, decomposing pesticide would take millennia
9. Proposal would allow wild animals to roam North America
10. Passage of Marin County GMO ban would encourage widespread use of harsh pesticides
11. Passage of GMO ban in San Luis Obispo would encourage use of harsh pesticides

Post Your Comments:
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... 30, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... BioPharma, Inc. has added another internationally recognized researcher ... is an internationally recognized researcher in bio-inspired materials ... at Peking University, China , ... University of North Carolina, Chapel Hill. Following a ...
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... Md. , March 30, 2015  Spherix ... company committed to the fostering and monetization of ... v. VTech,  Case No. 3:13-cv-03494-M and  Spherix v. ... United States District Court for the Northern District ... update regarding Spherix v. Verizon, Case ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: